ストックスクリーナーアプリを入手
12.88
1.02%
0.13
アフターアワーズ：
12.89
0.010
+0.08%
前日終値:
$12.75
開ける：
$12.72
24時間の取引高:
327.65K
Relative Volume:
0.83
時価総額：
$461.81M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+10.94%
1か月 パフォーマンス:
+60.80%
6か月 パフォーマンス:
+186.86%
1年 パフォーマンス:
+180.61%
1日の値動き範囲:
$12.55
$13.06
1週間の範囲:
$11.05
$13.10
52週間の値動き範囲:
$2.88
$13.10
Bioage Labs Inc Stock (BIOA) Company Profile
BIOA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
12.88 | 457.15M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | アップグレード | Citigroup | Neutral → Buy |
| 2025-02-28 | 開始されました | William Blair | Mkt Perform |
| 2024-12-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-10-21 | 開始されました | Citigroup | Buy |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-21 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Bioage Labs Inc (BIOA) 最新ニュース
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - Nasdaq
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool
Paul Rubin Sells 18,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
Morgan Stanley Upgrades BioAge Labs (BIOA) - Nasdaq
BioAge Labs (BIOA) Competitors and Alternatives 2025 - MarketBeat
Volume Recap: How BioAge Labs Inc stock reacts to Fed rate cutsFed Meeting & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Paul Rubin Sells 68,897 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen - MarketBeat
BioAge Labs CMO Paul D. Rubin Sells All Common Stock Holdings - TradingView
Officer Rubin Sells 68,897 ($701.9K) Of BioAge Labs Inc [BIOA] - TradingView
BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data - Investing.com South Africa
How BioAge Labs Inc. stock reacts to Fed rate cutsShort Setup & Fast Gain Stock Trading Tips - Newser
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial - Investing.com Nigeria
Is BioAge Labs Inc. stock a safe haven assetQuarterly Earnings Summary & Safe Entry Zone Identification - Newser
Why BioAge Labs Inc. stock remains undervaluedCEO Change & Smart Money Movement Alerts - Newser
How BioAge Labs Inc. (Y7G) stock stacks up against competitorsInsider Selling & Daily Chart Pattern Signal Reports - Newser
Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs - TipRanks
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Officer Rubin Files To Sell 68,897 Of BioAge Labs Inc [BIOA] - TradingView
Will BioAge Labs Inc. (Y7G) stock outperform global peersCEO Change & Safe Capital Investment Plans - Newser
Merger Talk: Is BioAge Labs Inc stock a safe haven assetPortfolio Growth Summary & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues - marketscreener.com
BioAge Reports Positive Interim Phase 1 Data For BGE-102; Shares Rise - Nasdaq
BioAge Labs Announces Positive Phase 1 Trial Results - TipRanks
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - markets.businessinsider.com
BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView — Track All Markets
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial By Investing.com - Investing.com South Africa
Is BioAge Labs Inc. (Y7G) stock a buy before new product rolloutJuly 2025 Outlook & Long Hold Capital Preservation Plans - Newser
Is BioAge Labs Inc. (Y7G) stock bottoming after sell off2025 Major Catalysts & Daily Volume Surge Trade Alerts - Newser
Bioage Labs (BIOA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is BioAge Labs Inc. (Y7G) stock supported by free cash flowVolume Spike & Fast Moving Stock Watchlists - Newser
Jefferies Financial Group Inc. Buys Shares of 50,000 BioAge Labs, Inc. $BIOA - MarketBeat
What analysts say about BioAge Labs Inc Y7G stockFibonacci Extensions & Rapid Capital Trading Tips - earlytimes.in
Dhanalaxmi Roto Spinners Limited Stock Analysis Technical Signals for YEARCash Flow Trends & Invest With Confidence - earlytimes.in
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - Sahm
Recent uptick might appease BioAge Labs, Inc. (NASDAQ:BIOA) institutional owners after losing 55% over the past year - Yahoo Finance
Is BioAge Labs Inc a good long term investmentCapital Gains Strategies & Small Budget Portfolio Growth - earlytimes.in
BioAge stock craters 70% on obesity drug study halt (update) - MSN
Is BioAge Labs Inc. stock recession proofStop Loss & Free Weekly Watchlist of Top Performers - newser.com
Will BioAge Labs Inc. (Y7G) stock hit analyst forecastsBuy Signal & Expert Curated Trade Ideas - newser.com
BioAge Labs (BIOA) Price Target Increased by 20.83% to 9.86 - MSN
Is BioAge Labs Inc. (Y7G) stock a buy on weakness2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
How interest rate cuts could boost BioAge Labs Inc. stock2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Bioage Labs Inc (BIOA) 財務データ
Bioage Labs Inc (BIOA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Bioage Labs Inc (BIOA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Dec 09 '25 |
Sale |
12.00 |
18,000 |
216,000 |
0 |
1.48%
0.09%
大文字化:
|
ボリューム (24 時間):